An observational study in Epilepsy, sponsored by UCB Pharma. Completed. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2012-05-28.
Sponsored by UCB Pharma · Observational
To evaluate, over 1 year period, the efficacy and safety of newly prescribed levetiracetam as add-on treatment (POS, myoclonoc seizures in JME and PGTCS in IGE) or primary monotherapy (partial onset seizures) in adult and paediatric patients within the approved age limits in routine clinical practice in Czech and Slovak Republics, Hungary, and Romania. Non-interventional study.
1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.
This study's enrollment of 2,569 is above the median of 102 across 521 observational studies indexed under Epilepsy.
Browse Epilepsy studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary care clinics and hospitals.
Exclusion Criteria:
Patients treated with Levetiracetam
Retention rate after 6 and 12 months
Time frame: 6 and 12 months
Seizure freedom for the last 6 and 12 months
Time frame: 6 and 12 months
No study locations are listed for this record.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma